CARA - Cara Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Stamford,
United States
Type: Equity
CARA price evolution
CARA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $52.18 | $63.28 | $58.66 | $47.8 |
| Short term investments | $48.98 | $15.67 | $36.44 | $66.89 |
| Net receivables | $3.32 | $5.03 | $10.54 | $6.56 |
| Inventory | $2.82 | $3.27 | $3.42 | $3.52 |
| Total current assets | $116.16 | $100.6 | $124.74 | $142.66 |
| Long term investments | $1.5 | $6.25 | $8.55 | $9.07 |
| Property, plant & equipment | $8.19 | $8.49 | $1.1 | $1.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.69 | $14.73 | $9.65 | $10.62 |
| Total investments | $50.48 | $21.91 | $44.99 | $75.97 |
| Total assets | $125.84 | $115.34 | $134.39 | $153.28 |
| Current liabilities | ||||
| Accounts payable | $25.59 | $22.38 | $24.48 | $15.22 |
| Deferred revenue | ||||
| Short long term debt | $0.5 | $0.98 | $1.46 | |
| Total current liabilities | $25.59 | $22.88 | $25.46 | $16.68 |
| Long term debt | $43.17 | $6.82 | ||
| Total noncurrent liabilities | $43.17 | $6.82 | ||
| Total debt | $43.17 | $7.31 | $0.98 | $1.46 |
| Total liabilities | $68.76 | $29.7 | $25.46 | $16.68 |
| Shareholders' equity | ||||
| Retained earnings | -$684.75 | -$652.41 | -$624.38 | -$592.9 |
| Other shareholder equity | -$0.26 | -$0.44 | -$0.73 | -$1.1 |
| Total shareholder equity | $57.09 | $85.64 | $108.93 | $136.6 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $52.18 | $64.15 | $13.86 | $32.09 |
| Short term investments | $48.98 | $81.66 | $153.58 | $149.24 |
| Net receivables | $3.32 | $4.45 | $0.46 | $0.56 |
| Inventory | $2.82 | $2.38 | $2.58 | |
| Total current assets | $116.16 | $168.91 | $173.29 | $195.06 |
| Long term investments | $1.5 | $11.35 | $69.75 | $70.56 |
| Property, plant & equipment | $8.19 | $1.98 | $3.6 | $5.12 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.69 | $13.33 | $73.77 | $76.09 |
| Total investments | $50.48 | $93.01 | $223.34 | $219.81 |
| Total assets | $125.84 | $182.24 | $247.06 | $271.16 |
| Current liabilities | ||||
| Accounts payable | $25.59 | $9.6 | $15.86 | $16.88 |
| Deferred revenue | ||||
| Short long term debt | $1.92 | $1.75 | $1.6 | |
| Total current liabilities | $25.59 | $23.46 | $17.62 | $18.48 |
| Long term debt | $43.17 | $1.92 | $3.67 | |
| Total noncurrent liabilities | $43.17 | $1.92 | $3.67 | |
| Total debt | $43.17 | $1.92 | $3.67 | $5.28 |
| Total liabilities | $68.76 | $23.46 | $19.53 | $22.16 |
| Shareholders' equity | ||||
| Retained earnings | -$684.75 | -$566.23 | -$480.76 | -$392.32 |
| Other shareholder equity | -$0.26 | -$1.67 | -$0.36 | $0.07 |
| Total shareholder equity | $57.09 | $158.78 | $227.52 | $249 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3 | $4.87 | $6.93 | $6.17 |
| Cost of revenue | $0.61 | $1.56 | $1.42 | $2.59 |
| Gross Profit | $2.4 | $3.31 | $5.51 | $3.58 |
| Operating activities | ||||
| Research & development | $28.41 | $25.45 | $30.31 | $24.33 |
| Selling, general & administrative | $6.59 | $6.75 | $7.54 | $6.89 |
| Total operating expenses | $35 | $32.21 | $37.85 | $31.23 |
| Operating income | -$32.61 | -$28.9 | -$32.34 | -$27.65 |
| Income from continuing operations | ||||
| EBIT | -$31.73 | -$28.03 | -$31.48 | -$26.66 |
| Income tax expense | ||||
| Interest expense | $0.6 | |||
| Net income | ||||
| Net income | -$32.34 | -$28.03 | -$31.48 | -$26.66 |
| Income (for common shares) | -$32.34 | -$28.03 | -$31.48 | -$26.66 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $20.97 | $41.87 | $23.03 | $135.08 |
| Cost of revenue | $6.17 | $7.27 | ||
| Gross Profit | $14.79 | $34.6 | $23.03 | $135.08 |
| Operating activities | ||||
| Research & development | $108.51 | $91.88 | $82.7 | $107.85 |
| Selling, general & administrative | $27.78 | $30.26 | $29.41 | $21.85 |
| Total operating expenses | $136.29 | $122.14 | $112.11 | $129.7 |
| Operating income | -$121.5 | -$87.53 | -$89.08 | $5.38 |
| Income from continuing operations | ||||
| EBIT | -$117.91 | -$85.47 | -$88.44 | $7.72 |
| Income tax expense | -$0.69 | |||
| Interest expense | $0.6 | |||
| Net income | ||||
| Net income | -$118.51 | -$85.47 | -$88.44 | $8.41 |
| Income (for common shares) | -$118.51 | -$85.47 | -$88.44 | $8.41 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$32.34 | -$28.03 | -$31.48 | -$26.66 |
| Operating activities | ||||
| Depreciation | $0.94 | $0.52 | $0.44 | $0.43 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.6 | $3.33 | $3.44 | $3.35 |
| Total cash flows from operations | -$17.37 | -$19.64 | -$20.45 | -$34.62 |
| Investing activities | ||||
| Capital expenditures | -$2.05 | -$0.32 | ||
| Investments | -$28.15 | $23.48 | $32.8 | $17.71 |
| Total cash flows from investing | -$30.2 | $23.16 | $32.8 | $17.71 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | $1.12 | $0.56 | |
| Net borrowings | $36.47 | |||
| Total cash flows from financing | $36.48 | $1.12 | $0.56 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$11.1 | $4.63 | $12.36 | -$16.35 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$118.51 | -$85.47 | -$88.44 | $8.41 |
| Operating activities | ||||
| Depreciation | $2.33 | $1.67 | $1.55 | $1.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.73 | $17.73 | $20.79 | $14.84 |
| Total cash flows from operations | -$92.08 | -$78.73 | -$60.09 | -$5.49 |
| Investing activities | ||||
| Capital expenditures | -$2.38 | -$0.04 | $0.03 | -$0.35 |
| Investments | $45.84 | $128.75 | -$4.78 | -$19.93 |
| Total cash flows from investing | $43.46 | $128.71 | -$4.75 | -$20.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.68 | $0.31 | $46.61 | $39.14 |
| Net borrowings | $36.47 | |||
| Total cash flows from financing | $38.15 | $0.31 | $46.61 | $39.14 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$10.47 | $50.29 | -$18.23 | $13.38 |
News
Fundamentals
| Market cap | $36.01M |
|---|---|
| Enterprise value | $27.00M |
| Shares outstanding | 54.48M |
| Revenue | $20.97M |
|---|---|
| EBITDA | -$115.58M |
| EBIT | -$117.91M |
| Net Income | -$118.51M |
| Revenue Q/Q | -7.88% |
| Revenue Y/Y | -49.92% |
| P/E ratio | -0.30 |
|---|---|
| EV/Sales | 1.29 |
| EV/EBITDA | -0.23 |
| EV/EBIT | -0.23 |
| P/S ratio | 1.72 |
| P/B ratio | 0.63 |
| Book/Share | 1.05 |
| Cash/Share | 0.96 |
| EPS | -$2.18 |
|---|---|
| ROA | -89.64% |
| ROE | -122.10% |
| Debt/Equity | 1.20 |
|---|---|
| Net debt/EBITDA | -0.14 |
| Current ratio | 4.54 |
| Quick ratio | 4.43 |